LEBWOHL, M.; STROBER, B.; LINABERRY, M.; HOYT, K.; BANERJEE, S.; KISA, R. M.; MEHTA, N. N. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: evaluation of lipid parameters in the phase 3 POETYK PSO-1 and PSO-2 trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 2, p. s115, 2023. DOI: 10.25251/skin.7.supp.115. Disponível em: https://jofskin.org/33014/index.php/skin/article/view/1966. Acesso em: 4 jul. 2024.